# Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)

Source: https://nuclide.cc/pairings/rituximab-then-ibritumomab-tiuxetan/  
Nuclide record `rituximab-then-ibritumomab-tiuxetan` (Pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Before giving the radioactive lymphoma treatment Zevalin, doctors first give a dose of the antibody drug rituximab. This clears out normal B-cells in the blood so the radioactivity goes to the lymphoma more precisely, and it is a mandatory step on the drug's official label, not an optional extra.

## Summary

Ibritumomab tiuxetan (Zevalin), a yttrium-90-labelled anti-CD20 radioimmunotherapy, is administered only as part of a fixed two-step regimen defined in its FDA label and EMA product information. On day 1, patients receive rituximab 250 mg/m2 by intravenous infusion; seven to nine days later, a second rituximab infusion (250 mg/m2) is given, followed within four hours by the therapeutic yttrium-90 ibritumomab tiuxetan infusion, dosed at 0.4 mCi/kg (14.8 MBq/kg) for patients with platelet counts of 150,000/mm3 or more, or a reduced 0.3 mCi/kg (11.1 MBq/kg) for platelet counts of 100,000-149,000/mm3, with a maximum activity cap of 32 mCi regardless of body weight.

The pharmacological rationale, stated explicitly in the EMA summary of product characteristics, is that rituximab pretreatment clears circulating and marginal-zone CD20-positive B-cells, which would otherwise act as a radioactivity 'sink' and reduce the fraction of the yttrium-90 dose reaching lymphoma cells; the rituximab dose used in the Zevalin regimen is deliberately lower than the dose used when rituximab is given as monotherapy. Zevalin is approved for relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma, and as consolidation after first-line induction chemotherapy in previously untreated follicular lymphoma (the latter still requiring the same rituximab-then-Zevalin sequence).

Because rituximab must be ordered and administered separately from the Zevalin kit, this is one of the clearest examples of a mandated, label-level drug sequence in radiopharmaceutical practice: Zevalin cannot be lawfully administered without preceding rituximab, and the labels carry boxed warnings for infusion reactions (during the rituximab step) and for prolonged, severe cytopenias following the radiolabelled step.

## Fields

- Kind: Pairing
- Last checked: 2026-09-22
- Tags: lymphoma; radioimmunotherapy; mandatory sequence
- Pairs: Rituximab + Ibritumomab tiuxetan
- Type: sequence
- Rationale: Rituximab pretreatment clears circulating and marginal-zone CD20-positive B-cells that would otherwise compete for binding, so the radiolabelled antibody given afterwards delivers more of its radiation dose specifically to lymphoma cells.
- Evidence: The FDA label and EMA SmPC for Zevalin mandate a fixed two-step regimen: rituximab 250 mg/m2 on day 1, then a second rituximab 250 mg/m2 infusion on day 7-9 followed within 4 hours by yttrium-90 ibritumomab tiuxetan at 0.4 mCi/kg (or 0.3 mCi/kg if platelets 100,000-149,000/mm3), capped at 32 mCi total.

## Sources

- FDA label: Zevalin (ibritumomab tiuxetan), 2018 revision: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125019s227lbl.pdf
- EMA product information: Zevalin (rituximab pretreatment rationale and dosing): https://ec.europa.eu/health/documents/community-register/2020/20200211147169/anx_147169_en.pdf

## Connected records

- targets: [CD20](https://nuclide.cc/targets/cd20/)
- indications: [Diffuse large B-cell lymphoma](https://nuclide.cc/indications/dlbcl/), [Follicular lymphoma](https://nuclide.cc/indications/follicular-lymphoma/)
- technologies: [Radio-antibody & radio-ADC](https://nuclide.cc/technologies/radioimmunotherapy/)
- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- drugs: [Ibritumomab tiuxetan](https://nuclide.cc/drugs/ibritumomab-tiuxetan/), [Rituximab](https://nuclide.cc/drugs/rituximab/)

---
JSON: https://nuclide.cc/api/v1/entities/rituximab-then-ibritumomab-tiuxetan.json